Report Store Get Proposal

Home Blog Hematological disorders 5

Hematological Disorders

Snippets - A Small piece of News or Article

Breakthrough Success: AUGMENT-101 Trial Hits Primary Endpoint with Consistent CR/CRh Rates Across Adult and Pediatric KMT2Ar AML and ALL Cohorts

Date of Abstract presentation12th December 2023IndicationsAcute LeukemiaAbstract NumberLBA-5Abstract typePoster According to the data presented at the ASH 2023 conference, as of the July 2023 data cutoff, the pivotal trial AUGMENT-101 included 94 patients with acute leukemia within the KMT2Ar cohorts. Among them, 57 individuals received central confirmation of their KMT2Ar status, had adequate follow-up, and were part of the population evaluated for efficacy. Among the patients evaluated for efficacy, a notable 63% demonstrated an overall response, while 44% achieved a composite response (CRc). Minimal residual disease (MRD) status was examined in 22 out of the 25...

Explore More...

Pharma News for BioMarin, CellTrans, Genenta, GSK

First Gene Therapy for Severe Hemophilia A; FDA Approves CellTrans’s Type 1 Diabetes Cellular Therapy; FDA Approve Amneal’s Parkinson’s Drug Over Safety Concerns; NLS Pharmaceutics’s Phase III Clinical Trials of Quilience; Genenta Science’s Temferon for the Treatment of Glioma; FDA Fast Track Designation to GSK’s Gonorrhea Drug

MedTech news for Eko. Haemonetics. Roche, Medtronic, Biodesix

GE HealthCare, DePuy Synthes Announced Collaboration; Eko Health Launched CORE 500 Digital Stethoscope; Haemonetics’s NexSys PCS Plasma Collection System; Roche’s Alzheimer’s Disease Cerebrospinal Fluid (CSF) Assays; Medtronic’s MiniMed 780G system; Biodesix’s VeriStrat Blood-Based Host Immune Classifier

Pharma News for Lexicon, Novartis, Takeda and HUTCHMED

FDA Approves Lexicon’s INPEFA (Sotagliflozin); PTC Therapeutics’s Vatiquinone MOVE-FA Registration-Directed Trial; EU Approval to Novartis’s Sickle Cell Disease Drug; EMA Approves Neoadjuvant Nivolumab/Chemotherapy in Resectable NSCLC; FDA Grants Priority Review to Fruquintinib for mCRC; FDA Orphan Drug Designation to Vega Therapeutics’s VGA039

pharma-news-for-bms-teva-biogen-atsena-kiromic

FDA Grants Priority Review to BMS’ Luspatercept; Teva and MedinCell’s Risperidone FDA Approval; Biogens’s QALSODY FDA Accelerated Approval; FDA IND Authorization to Kiromic’s Deltacel; Atsena’s ATSN-201 FDA IND Clearance

Pharma News for XORTX, Roche, Lantheus, Janssen, Daiichi Sankyo, bluebird bio, and POINT Biopharma Global

Janssen’s AKEEGA Approval; FDA Approves Roche’s Polivy Combo for Frontline B-cell Lymphoma; Daiichi Sankyo’s Quizartinib for Adults With FLT3-ITD-Positive AML; bluebird bio BLA for lovo-cel for Patients with Sickle Cell Disease; Fast Track Designation for Lu-PNT2002 for mCRPC Treatment; FDA Orphan Drug Designation to XORTX’s Oxypurinol

vertex-crispr-gene-editing-therapy-exa-cel

Vertex/CRISPR’s Gene-editing Therapy exa-cel: Inch Ahead of Rival

Pharma News and Updates for Incyte, Eisai, Biogen, Reata Pharmaceuticals, Genenta Science, Harbour BioMed, Ikena Oncology

Incyte’s Clinical Trial for Myelofibrosis; Eisai and Bioge’s Leqembi; FDA Approves Reata Pharmaceuticals’ SKYCLARYS; Temferon Lands FDA Orphan Drug Status for Glioblastoma; Harbour BioMed Announces Results from Phase III Trial of Batoclimab; FDA Fast Track Designation to Ikena’s AHR Antagonist IK-175

besremi-jakafi-rusfertide-for-polycythemia-vera-treatment

Polycythemia Vera Treatment: Besremi, Jakafi, and Rusfertide Analysis

Pharma News and Updates for Actinium, Apellis, Chiesi, IVERIC, Travere, Takeda

Actinium Announces Phase III SIERRA Trial Results; FDA Approves Apellis’s Geographic Atrophy Drug; FDA Gives Green Light to Chiesi’s Lamzede; FDA Accepts NDA and Grants Priority Review for Avacincaptad Pegol; FDA Approves Travere’s Kidney Disorder Drug; Takeda Presents Phase 3 GRAPHITE Study Results

latest-pharma-news-and-updates-for-eli-lilly-novartis-janssen-ipsen-kite

Eli Lilly’s Jaypirca Approval; Novartis’ Adakveo EMA Review; Janssen’s CARTITUDE-4 Study of CARVYKTI; Negative Review on Ipsen’s Palovarotene; Gilead Sciences and Kite’s Yescarta NICE Recommendations; Daiichi Sankyo and AstraZeneca’s Enhertu EU Approval

MedTech News for Cardiovascular Systems, Koneksa, Medcura, Abbott, Enovis, Bausch + Lomb, AcuFocus

First Patient Enrolled in Kaizen Clinical Study in Japan; Koneksa’s At-Home Mobile Spirometry Clinical Trial; Medcura’s LifeGel™ Absorbable Surgical Hemostat; FDA Clearance to Abbott’s NAVITOR; Enovis’s DynaClip Delta™ and DynaClip Quattro™ bone staples; Bausch + Lomb Acquired AcuFocus

Pharma News and Updates for Gilead, Biogen, Pfizer, MediWound, UCB

Gilead Buys Out Rights to Cancer Therapy from Jounce; FDA Places Clinical Hold on Biogen’s Orelabrutinib; Pfizer Announces Phase 3 BENEGENE-2 Study Result; FDA Approves MediWound’s NexoBrid; UCB Announces FDA Acceptance of BLA Resubmission for Bimekizumab; FDA Approves TG Therapeutics’ Briumvi

Pharma News and Updates for AbbVie, Ferring, Merck, CSL, Amicus, Takeda

Fourth FDA Approval for AbbVie’s Vraylar; FDA Approves Ferring’s Adstiladrin for NMIBC; Merck and Moderna’s mRNA Cancer Vaccine Trial; EMA Recommends the CSL’s Gene Therapy for Hemophilia B; CHMP Backs Amicus’ Pompe Disease Therapy; Takeda Announces the Phase 3 AURORA Study Result

ASH Annual Meeting, Major Abstracts, Breakthroughs, Updates, and News

ASH 2022 Annual Meeting – Insights Into Major Diffuse Large B-cell Lymphoma (DLBCL) Abstract and Breakthroughs

emerging-therapies-for-cutaneous-t-cell-lymphoma-treatment

How Will the Emerging Therapies for Cutaneous T-cell Lymphoma Reshuffle its Treatment Landscape

Pharma News for Amgen, AstraZeneca, Sanofi, Anavex, Sensorion, GSK

Amgen’s Olpasiran Candidate; GSK’s Novel Antibiotic for Urinary Tract Infections; AstraZeneca and Sanofi’s Beyfortus Approval; FDA Orphan Designation to Anavex’s Anavex2-73; FDA Rare Pediatric Disease Designation to Sensorion’s OTOF-GT; GSK’s Blenrep Fails in Phase III Trial in R/R Multiple Myeloma

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly